Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
|
| In millions, except per share items | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Personalized Genetic Health | 1,652.8 | 1,849.6 | 2,296.1 | | | | | |
| Renal and Endocrinology | 1,070.1 | 1,008.4 | 954.4 | | | | | |
| Hematology and Oncology | 678.8 | 512.9 | 309.5 | | | | | |
| Biosurgery | 628.8 | 561.8 | 491.1 | 426.6 | 387.6 | 353.2 | 209.5 | 253.3 |
| Other | 18.3 | 44.6 | 76.2 | 3,386.9 | 2,799.4 | 2,381.7 | 1,991.6 | 1,460.6 |
| Total revenues [+] | 4,048.7 | 3,977.3 | 4,127.4 | 3,813.5 | 3,187.0 | 2,734.8 | 2,201.1 | 1,713.9 |
| Products | 3,999.9 | 3,910.1 | 4,040.0 | 3,457.8 | 2,887.4 | 2,453.3 | 1,976.2 | 1,563.5 |
| Services | 45.3 | 46.8 | 45.4 | 326.3 | 282.1 | 261.4 | 212.4 | 131.0 |
| Revenue growth [+] | 1.8% | -3.6% | 8.2% | 19.7% | 16.5% | 24.2% | 28.4% | 28.9% |
| Personalized Genetic Health | -10.6% | -19.4% | | | | | | |
| Renal and Endocrinology | 6.1% | 5.7% | | | | | | |
| Hematology and Oncology | 32.3% | 65.7% | | | | | | |
| Biosurgery | 11.9% | 14.4% | 15.1% | 10.1% | 9.7% | 68.6% | -17.3% | |
| Other | -48.6% | -43.4% | -92.3% | 14.0% | 217.0% | 13.0% | 110.3% | |
| Cost of goods sold [+] | 1,191.5 | 1,070.3 | 855.1 | 927.3 | 536.4 | 462.2 | 448.4 | 400.0 |
| Cost of product sales | 1,153.7 | 1,040.2 | 825.9 | 715.5 | | | | |
| Cost of services | 37.9 | 30.1 | 29.2 | 211.8 | 199.3 | 170.5 | 140.1 | 75.7 |
| Gross profit | 2,857.2 | 2,906.9 | 3,272.3 | 2,886.2 | 2,650.6 | 2,272.7 | 1,752.7 | 1,313.9 |
| Gross margin | 70.6% | 73.1% | 79.3% | 75.7% | 83.2% | 83.1% | 79.6% | 76.7% |
| Selling, general and administrative | 1,553.9 | 1,244.4 | 1,172.7 | 1,187.2 | 1,010.4 | 787.8 | 599.4 | 520.0 |
| Research and development | 847.3 | 833.9 | 1,294.4 | 737.7 | 650.0 | 502.7 | 391.8 | 335.3 |
| Equity in earnings | -3.0 | | 0.2 | 7.4 | 15.7 | 0.2 | -15.6 | -16.7 |
| Other operating expenses | 364.7 | 319.1 | 212.6 | 201.1 | 627.9 | 352.1 | 254.1 | 269.6 |
| EBITDA [+] | 583.7 | 966.0 | 967.5 | 1,105.8 | 587.5 | 811.8 | 696.9 | 332.8 |
| EBITDA growth | -39.6% | -0.2% | -12.5% | 88.2% | -27.6% | 16.5% | 109.4% | 99.3% |
| EBITDA margin | 14.4% | 24.3% | 23.4% | 29.0% | 18.4% | 29.7% | 31.7% | 19.4% |
| Depreciation and amortization | 233.2 | 202.9 | 162.1 | 137.1 | | | 95.6 | 80.2 |
| EBITA | 350.5 | 763.1 | 805.4 | 968.7 | 587.5 | 811.8 | 601.3 | 252.6 |
| EBITA margin | 8.7% | 19.2% | 19.5% | 25.4% | 18.4% | 29.7% | 27.3% | 14.7% |
| Amortization of intangibles | 262.3 | 253.5 | 212.6 | 201.1 | 209.4 | 181.6 | 109.5 | 80.3 |
| EBIT [+] | 88.2 | 509.6 | 592.8 | 767.6 | 378.1 | 630.2 | 491.8 | 172.3 |
| EBIT growth | -82.7% | -14.0% | -22.8% | 103.0% | -40.0% | 28.1% | 185.4% | 78.3% |
| EBIT margin | 2.2% | 12.8% | 14.4% | 20.1% | 11.9% | 23.0% | 22.3% | 10.1% |
| Non-recurring items [+] | 55.4 | | 2.0 | 106.4 | 552.9 | 29.2 | 254.5 | 158.0 |
| In-process research & development | | | | 106.4 | 552.9 | 29.2 | 254.5 | 158.0 |
| Interest income, net [+] | 4.4 | 17.6 | 46.9 | 58.0 | -15.5 | -19.6 | -38.2 | -26.6 |
| Interest expense | 7.0 | | 4.4 | 12.1 | 15.5 | 19.6 | 38.2 | 26.6 |
| Interest income | 11.4 | 17.6 | 51.3 | 70.2 | | | | |
| Other income (expense), net [+] | -29.9 | 22.5 | -3.1 | 16.4 | 137.6 | 47.5 | 28.6 | 17.3 |
| Gain (loss) on investments | | | | 13.1 | | | | |
| Other | 0.5 | -1.6 | 0.3 | 3.3 | 2.0 | 1.5 | 0.4 | -1.0 |
| Pre-tax income | 7.3 | 549.7 | 634.7 | 735.7 | -52.7 | 628.9 | 227.7 | 5.1 |
| Income taxes | -24.8 | 122.8 | 207.6 | -255.5 | -35.9 | 187.4 | 141.2 | 72.6 |
| Tax rate | | 22.3% | 32.7% | | 68.1% | 29.8% | 62.0% | 1437.1% |
| Minority interest | | | | | 10.4 | 12.0 | 6.0 | 2.2 |
| Earnings from continuing ops | 32.1 | 853.9 | 854.2 | 480.2 | -16.8 | 441.5 | 86.5 | |
| Earnings from discontinued ops | 390.1 | -4.6 | -6.0 | | | | | |
| Net income | 422.1 | 849.2 | 848.2 | 480.2 | -16.8 | 441.5 | 86.5 | 0.0 |
| Net margin | 10.4% | 21.4% | 20.6% | 12.6% | -0.5% | 16.1% | 3.9% | 0.0% |
| |
| Basic EPS [+] | $0.12 | $3.18 | $3.18 | $1.82 | ($0.06) | $1.73 | $0.38 | |
| Growth | -96.1% | -0.2% | 74.8% | -2934.2% | -103.7% | 357.0% | | |
| Diluted EPS [+] | $0.12 | $3.12 | $2.99 | $1.71 | ($0.06) | $1.62 | $0.37 | |
| Growth | -96.2% | 4.2% | 74.9% | -2763.9% | -104.0% | 339.2% | | |
| |
| Shares outstanding (basic) [+] | 261.5 | 268.8 | 268.5 | 263.9 | 261.6 | 254.8 | 228.2 | |
| Growth | -2.7% | 0.1% | 1.7% | 0.9% | 2.7% | 11.7% | | |
| Shares outstanding (diluted) [+] | 268.6 | 274.1 | 285.6 | 280.8 | 261.6 | 272.2 | 234.3 | |
| Growth | -2.0% | -4.0% | 1.7% | 7.3% | -3.9% | 16.2% | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|